The Department of Pharmacy, Medicines and Pharmacopeia is one of the ten technical departments of the Ministry of Public Health in Chad. This department oversees regulatory activities, as well as the implementation and evaluation of policies in the field of pharmacy, medicines and pharmacopoeia (Oulech, n.d.-a). The prime focus of the sub-directorate of pharmacy and medicines is to provide pharmacy, medicine, quality control, pharmaceutical inspection and pharmacovigilance services (Oulech, n.d.-b).

Product registration is a sub-section of the medicine service, a responsibility of the sub-directorate of pharmacy and medicines (Oulech, n.d.-b). Conversely, the processes involved in the registration are currently not available. The technologies that are used during this process are also not available.

According to the website of the ministry of public health, the inspections of pharmaceutical establishments and laboratories for Good Manufacturing and Good Distributions Practices is the responsibility of the inspector in charge of pharmaceutical establishments and laboratories (Oulech, n.d.-a).
They collaborate with the sub-directorate for pharmacy and medicines to ensure that pharmaceutical institutions, abide by the regulations indicated. The information on the processes used before, during and after inspections have been conducted is not available. There is also no information on the technologies used in this process.

Pharmacovigilance is one of the primary services of the sub-directorate of the pharmacy and medicines. This division focuses on gathering and evaluating the information on adverse drug reactions (Oulech, n.d.-b). Out of the information gathered, reports and guides are drawn out to assess the impact of adverse drug reactions.
Training is also given to health professionals on the importance of pharmacovigilance and to raise patient awareness. Health workers are to report adverse drug reactions by filling the adverse drug reaction form (Oulech, n.d.-b). The division’s main goal is to ensure that defined policies and strategies are implemented and evaluated to improve the established processes.
However, there is no information on the proposed procedures used during pharmacovigilance, how adverse drug reaction forms are derived, or the technologies used in pharmacovigilance.

According to a survey conducted by the WHO and Global Fund, clinical trials are not conducted in Chad (WHO & Global Fund, 2011).

Per a survey conducted in 2011, post-market surveillance studies are not conducted. Inspectors do not collect samples for post-market surveillance (WHO & Global Fund, 2011).

Regarding import and export, pharmaceutical products are imported in Chad to a large extent. Since 1996, the Pharmaceutical Purchasing Centre has supplied the pharmaceutical public sector in Chad (US Commercial Service, 2017). It is indicated that there is better coordination in terms of the supply of medicines to the public sector. Chad, however, faces the challenge of preservation of medications. However, a suggested solution is to build a drug manufacturing plant in Chad (Chad- Wholesale Trade / Pharmaceuticals, 2019).

Per information given, only licensed medical officers and pharmacist can apply to establish pharmacies in Chad (US Commercial Service, 2017).

Monitoring and evaluation are conducted in Chad; however, there is no information regarding the processes involved with monitoring and evaluation (WHO & Global Fund, 2011).